Skip to main content

Table 1 Characteristics of the included trials

From: Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials

Study ID

Subject

Mean age of Saffron group (year)

Mean age of control group (year)

Sample size, gender (F/M)

Study design

Form of saffron

Dosage (mg/day)

Control, mg/day

Duration (wk)

Outcome Measurement

Akhondzadeh 2010 [16]

AD

72.70 ± 6.20

73.85 ± 4.63

54 (25/29)

multicentre, double blind RCT

extract

30

donepezil, 10

22

ADAS-cog, CDR-SB, safety

Akhondzadeh 2010 [17]

AD

72.65 ± 3.89

73.13 ± 4.70

46 (21/25)

double blind RCT

extract

30

placebo

16

ADAS-cog, CDR-SB, safety

Farokhnia 2014 [18]

moderate to severe AD

77.73 ± 8.05

77.47 ± 7.99

68 (29/39)

double blind RCT

extract

30

memantine, 20

48

SCIRS, FAST, MMSE, safety

Tsolaki 2016 [19]

MCI

71.47 ± 6.73

69.72 ± 7.33

35 (26/9)

single blind, parallel RCT

powder

125

no treatment

48

MMSE, FRSSD, MoCA, NPI, GDS, MRI, EEG

  1. Notes: AD Alzheimer’s disease; MCI Mild cognitive disorder; ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale; CDR-SB Clinical dementia rating scale-sums of boxes; MMSE Mini-Mental State Examination; MoCA Montreal Cognitive Assessment; FRSSD Functional Rating Scale for Symptoms of Dementia; SCIRS Severe Cognitive Impairment Rating Scale; FAST Functional Assessment Staging; NPI Neuropsychiatric Inventory; GDS Geriatric Depression Scale